Chia Tai Tianqing Pharmaceutical Group Co., Ltd. clinical trial pipeline

6 trials changed in the last 30 days: 0 stopped, 3 with notable changes, 3 with minor changes only.

1. Notable

   Inhaled TQC3721 Suspension · Moderate-to-Severe Chronic…Inhaled TQC3721 Suspension · Moderate-to-Severe Chronic Obstructive Pulmonary Disease

   Primary endpoint(s) modified

   Also in this update: Recruitment opened; Trial sites reduced: 79 → 54 locations

   Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3· NCT07464587· Registry history of NCT07464587 on ClinicalTrials.gov (opens the registry)

   Sep 28, 2026

2. Notable

   TQF3250 Capsules in Overweight/Obese Trial · Poor Weight Control…TQF3250 Capsules in Overweight/Obese Trial · Poor Weight Control Through Simple Lifestyle Intervention

   Recruitment opened

   Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1· NCT07798284· Registry history of NCT07798284 on ClinicalTrials.gov (opens the registry)

   Oct 16, 2026

3. Notable

   Treatment · Moderate to Severe Crohn's Disease With Tabellvi®

   Recruitment opened

   Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 4· NCT07663526· Registry history of NCT07663526 on ClinicalTrials.gov (opens the registry)

   Sep 24, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.